16 December 2020
Here Duncan Porter, Senior Director and leader of the Clinical Microbiology segment at Thermo Fisher Scientific, discusses how healthcare facilities have changed their focus from pathogen testing via qPCR to serology testing as a means to understand the immune response and epidemiology of the disease. Porter highlights how the COVID-19 pandemic has provided new opportunities for home testing as well as novel approaches for collection and transport to help innovate modern healthcare delivery.
This video is the final installment in our four-part series exploring the diagnostic labs of the future. Follow the links below for the complete series: